

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 8, 2014**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Merrimack Pharmaceuticals, Inc.

File No. 333-175427 - CF#31229

Merrimack Pharmaceuticals, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on July 8, 2011, as amended.

Based on representations by Merrimack Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.16	through July 8, 2017
Exhibit 10.17	through July 8, 2017
Exhibit 10.18	through July 8, 2017
Exhibit 10.19	through July 8, 2017
Exhibit 10.20	through July 8, 2017
Exhibit 10.21	through July 8, 2017
Exhibit 10.22	through July 8, 2017
Exhibit 10.24	through July 8, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kevin M. O'Neill
Deputy Secretary